CeriBell (NASDAQ:CBLL) Shares Down 9.2% - Should You Sell?

CeriBell (NASDAQ:CBLL - Get Free Report)'s share price traded down 9.2% during mid-day trading on Friday . The stock traded as low as $20.75 and last traded at $20.91. 77,666 shares changed hands during mid-day trading, a decline of 57% from the average session volume of 179,863 shares. The stock had previously closed at $23.02.

Wall Street Analyst Weigh In

A number of brokerages recently commented on CBLL. Canaccord Genuity Group raised their price objective on shares of CeriBell from $31.00 to $33.00 and gave the stock a "buy" rating in a report on Monday, December 9th. JPMorgan Chase & Co. assumed coverage on CeriBell in a report on Tuesday, November 5th. They issued an "overweight" rating and a $32.00 price target on the stock. Canaccord Genuity Group started coverage on CeriBell in a report on Tuesday, November 5th. They set a "buy" rating and a $30.00 price objective for the company. TD Cowen boosted their target price on CeriBell from $31.00 to $36.00 and gave the company a "buy" rating in a research note on Monday, December 9th. Finally, William Blair assumed coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued an "outperform" rating on the stock. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $32.60.

CeriBell Stock Down 9.1 %

The firm's fifty day simple moving average is $27.18.

CeriBell (NASDAQ:CBLL - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($1.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.82) by ($1.03). The business had revenue of $17.20 million for the quarter, compared to analysts' expectations of $17.06 million. As a group, equities research analysts predict that CeriBell will post -2.46 earnings per share for the current year.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.